Phase 2 Muscular Dystrophy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with a type of Myotonic Dystrophy Type 1 (DM1) where the genetic repeat causing the condition is larger than 100 repeats.
• Your muscle symptoms from DM1 started when you were 12 years old or older.
• You have noticeable muscle stiffness (myotonia), meaning it takes you at least 2 seconds to fully open your hand, as assessed by the study doctor.
• You have measurable strength in your hand grip and in lifting your foot upward at the ankle.
• You are able to walk a short distance, climb and descend stairs (for certain groups in the study), and stand up from a chair 5 times in a row — all without using walking aids like canes, walkers, or leg braces.

Who may not be able to join:

• You have had a major surgery in the last 12 weeks, or you are expected to have one (such as having a heart device implanted) during the study.
• You have a history of a severe allergic reaction (anaphylaxis).
• You have another health condition, unrelated to DM1, that significantly affects your ability to walk or take part in physical assessments.
• You have recently taken medications that can reduce muscle stiffness (myotonia), within a certain timeframe before your screening visit (confirm with trial site).
• Your heart's electrical activity (measured by an ECG) shows certain abnormalities, including a reading above specific limits or a significant heart conduction problem, as judged by the study doctor.
• Your lung function test shows that your breathing capacity is below 50% of what is expected for someone your age and size.
• You have had a biopsy of a specific muscle in your lower leg (tibialis anterior) within the past 3 months, or you plan to have one during the study for reasons unrelated to this trial.
• You have had a history of suicidal behaviour, a suicide attempt, or certain levels of suicidal thoughts within the past 6 months, or the study doctor considers you to be at significant risk.
• You have recently taken certain diabetes or weight-management medications (such as semaglutide, dulaglutide, liraglutide, exenatide, or tirzepatide) within a specific timeframe before your screening visit.
• Significant weight loss during the study may affect your eligibility or continued participation, as it could impact how the medication is dosed and how results are measured (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Note: This is not a complete list — additional criteria may apply. This information is provided for general understanding only and is not medical advice.